These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 31779657)

  • 1. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic agents for severe asthma patients: clinical perspectives and implications.
    Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
    Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
    Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
    Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological treatments in childhood asthma.
    Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
    Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice].
    Fomina DS; Mukhina OA; Lebedkina MS; Gadzhieva MK; Bobrikova EN; Sinyavkin DO; Parshin VV; Chernov AA; Belevskiy AS
    Ter Arkh; 2022 Mar; 94(3):413-419. PubMed ID: 36286907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis.
    Nachef Z; Krishnan A; Mashtare T; Zhuang T; Mador MJ
    J Asthma; 2018 Jan; 55(1):89-100. PubMed ID: 28459601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab (Nucala°) in asthma.
    Prescrire Int; 2017 Feb; 26(179):38-39. PubMed ID: 30726627
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial.
    Cornelius V; Babalis D; Carroll WD; Cunningham S; Fleming L; Gaillard E; Gupta A; Janani L; Kennington E; Murray C; Nagakumar P; Roberts G; Seddon P; Sinha I; Streatfield C; Weir E; Saglani S
    BMJ Open; 2024 Aug; 14(8):e090749. PubMed ID: 39174059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
    Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
    Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
    Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
    Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options of immunotherapeutic treatments for children with asthma.
    Porcaro F; Cutrera R; Pajno GB
    Expert Rev Respir Med; 2019 Oct; 13(10):937-949. PubMed ID: 31414917
    [No Abstract]   [Full Text] [Related]  

  • 18. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
    Han D; Lee JK
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.